Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The benzodiazepine site is an allosteric binding site on the GABAA receptor, located at the interface between alpha and gamma subunits. Binding of benzodiazepines to this site enhances GABA's effects, leading to increased chloride ion influx and neuronal inhibition. Different alpha subunit combinations confer distinct pharmacological properties, influencing sedation, anxiolysis, and other therapeutic effects.
Positive allosteric modulation of GABAA receptor activity, increasing the frequency of chloride channel opening in response to GABA.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Benzodiazepine Site of the GABAA Receptor (BZD Site).